The ISSCR has released a comprehensive resource, on ‘Best Practices for the Development of Pluripotent Stem Cell-Derived Cellular Therapies’, designed to accelerate the translation of human pluripotent stem cell(PSC)-derived therapies into clinical trials and commercial use.
The interactive resource was collaboratively developed by leading international experts in cell therapy, including CGT Catapult Chief Clinical Officer and co-chair of the ISSCR Best Practices Steering Committee, Jacqueline Barry. The document, designed for academics, industry scientists and regulators, outlines the key principles and decision points required to develop safe, effective, and regulatory compliant PSC-derived products.
View the resource on the ISSCR website: https://www.isscr.org/translational-best-practices
